Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third ... control of STX-478, described as a next-generation PI3K ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback